| Name | Title | Contact Details |
|---|
Vericel develops, manufactures, and markets autologous cell-based therapies for patients with serious diseases and conditions. The company markets two cell therapy products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is a third generation autologous cellularized scaffold product that is indicated for the repair of single or multiple symptomatic, full-thickness cartilage defects of the adult knee, with or without bone involvement. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel is also developing 1 additional cell product. Ixmyelocel-T is a multicellular therapy intended to treat advanced heart failure due to ischemic dilated cardiomyopathy (DCM). Developing autologous (patient`s own) cell therapies—with integrity Vericel uses rigorous scientific methods to develop novel therapies for the treatment of patients with autologous (patient`s own) cells. In addition, personal integrity, team work, collaboration, and innovative technology are the foundations of our work. We seek to practice transparency in our clinical trials and research, and in our relationships with each other, our patients, and the investors who support us.
At Nerium International, making people better means establishing a business that can bring real change to your life, your skin, and your personal development. Through our partnership with Nerium SkinCare, a division of Nerium Biotechnology, Inc., Nerium International markets breakthrough products validated by real science. These age-defying skincare products are distributed exclusively by our Independent Brand Partners.
Interleuken Genetics is a Waltham, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Myovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women`s health diseases and other endocrine-related disorders. Myovant`s lead product candidate is relugolix, an oral, once-daily, small molecule that acts as a GnRH receptor antagonist. Myovant is in the process of initiating five international Phase 3 clinical trials for relugolix, two in women with heavy menstrual bleeding associated with uterine fibroids, two in women with endometriosis-associated pain, and one in men with advanced prostate cancer. Myovant is simultaneously developing MVT-602, an analog of kisspeptin, for the treatment of female infertility as part of assisted reproduction. Over time, the company intends to expand its development pipeline to include other potential treatments for women`s health and endocrine-related disorders.
What if we told you that our bodies make use of only a few hundred different signaling pathways to control all of our 20,000 or so genes. We call it the gene circuitry code, unique for every gene in our body. CAMP4 has built a proprietary 4-D Gene Circuity Platform to codify the discrete set of combinatorial rules used by any human cell type central to disease pathology. By applying the power of computational biology and machine learning algorithms, CAMP4 is able to rapidly solve for druggable targets to control the output of any disease gene of interest.